Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Abstract Background The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2024-01-01
Цуврал:	Cancer Medicine
Нөхцлүүд:	abiraterone acetate angiotensin‐converting enzyme inhibitors antihypertensives castration‐resistant prostate cancer comedication enzalutamide
Онлайн хандалт:	https://doi.org/10.1002/cam4.6853
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!